ID   IGF1R_HUMAN             Reviewed;        1367 AA.
AC   P08069; B1B5Y2; Q14CV2; Q9UCC0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   02-NOV-2010, entry version 133.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Insulin-like growth factor I receptor;
DE            Short=IGF-I receptor;
DE   AltName: CD_antigen=CD221;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=IGF1R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 31-56; 446-453;
RP   503-524; 561-579; 668-672 AND 721-729.
RC   TISSUE=Placenta;
RX   MEDLINE=87053815; PubMed=2877871;
RA   Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C.,
RA   Henzel W., Bon T.L., Kathuria S., Chen E., Jacobs S., Francke U.,
RA   Ramachandran J., Fujita-Yamaguchi Y.;
RT   "Insulin-like growth factor I receptor primary structure: comparison
RT   with insulin receptor suggests structural determinants that define
RT   functional specificity.";
RL   EMBO J. 5:2503-2512(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92268129; PubMed=1316909;
RA   Abbot A.M., Bueno R., Pedrini M.T., Murray J.M., Smith R.J.;
RT   "Insulin-like growth factor I receptor gene structure.";
RL   J. Biol. Chem. 267:10759-10763(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal brain;
RA   Nagase T., Kikuno R.F., Yamakawa H., Ohara O.;
RL   Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-388 AND HIS-605.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31.
RX   MEDLINE=91282751; PubMed=1711844; DOI=10.1016/0006-291X(91)90654-P;
RA   Cooke D.W., Bankert L.A., Roberts C.T. Jr., Leroith D., Casella S.J.;
RT   "Analysis of the human type I insulin-like growth factor receptor
RT   promoter region.";
RL   Biochem. Biophys. Res. Commun. 177:1113-1120(1991).
RN   [7]
RP   PROTEIN SEQUENCE OF 31-45 AND 741-750, FUNCTION, AND FORMATION OF A
RP   HYBRID RECEPTOR WITH INSR.
RC   TISSUE=Placenta;
RX   MEDLINE=94079885; PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-
RT   I/insulin hybrid receptors by protein microsequencing and
RT   purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1137-1193, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   MEDLINE=94067791; PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [9]
RP   ENZYME REGULATION, AND BINDING OF MANGANESE.
RC   TISSUE=Placenta;
RX   MEDLINE=91009374; PubMed=2211730;
RA   Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.;
RT   "Substructural analysis of the insulin receptor by microsequence
RT   analyses of limited tryptic fragments isolated by sodium dodecyl
RT   sulfate-polyacrylamide gel electrophoresis in the absence or presence
RT   of dithiothreitol.";
RL   J. Biol. Chem. 265:18673-18681(1990).
RN   [10]
RP   FUNCTION, SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=1846292; DOI=10.1021/bi00215a008;
RA   Tollefsen S.E., Stoszek R.M., Thompson K.;
RT   "Interaction of the alpha beta dimers of the insulin-like growth
RT   factor I receptor is required for receptor autophosphorylation.";
RL   Biochemistry 30:48-54(1991).
RN   [11]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=8452530;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=7679099;
RA   Kato H., Faria T.N., Stannard B., Roberts C.T. Jr., LeRoith D.;
RT   "Role of tyrosine kinase activity in signal transduction by the
RT   insulin-like growth factor-I (IGF-I) receptor. Characterization of
RT   kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic
RT   antibody (alpha IR-3).";
RL   J. Biol. Chem. 268:2655-2661(1993).
RN   [13]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF TYR-980 AND
RP   LYS-1033.
RX   MEDLINE=95318150; PubMed=7541045; DOI=10.1074/jbc.270.26.15639;
RA   Craparo A., O'Neill T.J., Gustafson T.A.;
RT   "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate
RT   their phosphotyrosine-dependent interaction with the NPEY motif of the
RT   insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 270:15639-15643(1995).
RN   [14]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9355755;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [15]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/S0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors
RT   in human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [16]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=9822622; DOI=10.1074/jbc.273.48.31640;
RA   Lin F.-T., Daaka Y., Lefkowitz R.J.;
RT   "beta-arrestins regulate mitogenic signaling and clathrin-mediated
RT   endocytosis of the insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 273:31640-31643(1998).
RN   [17]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-980; TYR-1280; TYR-1281
RP   AND TYR-1346.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [18]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=11162456; DOI=10.1006/bbrc.2000.4046;
RA   Lopaczynski W., Terry C., Nissley P.;
RT   "Autophosphorylation of the insulin-like growth factor I receptor
RT   cytoplasmic domain.";
RL   Biochem. Biophys. Res. Commun. 279:955-960(2000).
RN   [19]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=12138094; DOI=10.1074/jbc.M202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [20]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15878855; DOI=10.1074/jbc.M501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of
RT   the insulin-like growth factor-1 receptor by acting as adaptor for the
RT   MDM2 E3 ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [21]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=16831875; DOI=10.1074/jbc.M605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like
RT   growth factor I receptor (IGF-IR) have low insulin and high IGF-1
RT   affinity irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1161; TYR-1165 AND
RP   TYR-1166, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1161; TYR-1165; SER-1339
RP   AND THR-1366, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1339, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1165; SER-1339; SER-1365
RP   AND THR-1366, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   VARIANTS IGF1RES GLN-138 AND ASN-145, AND CHARACTERIZATION OF VARIANTS
RP   IGF1RES GLN-138 AND ASN-145.
RX   PubMed=14657428; DOI=10.1056/NEJMoa010107;
RG   The intrauterine growth retardation (IUGR) study group;
RA   Abuzzahab M.J., Schneider A., Goddard A., Grigorescu F., Lautier C.,
RA   Keller E., Kiess W., Klammt J., Kratzsch J., Osgood D., Pfaeffle R.,
RA   Raile K., Seidel B., Smith R.J., Chernausek S.D.;
RT   "IGF-I receptor mutations resulting in intrauterine and postnatal
RT   growth retardation.";
RL   N. Engl. J. Med. 349:2211-2222(2003).
RN   [27]
RP   VARIANT IGF1RES GLN-739, AND CHARACTERIZATION OF VARIANT IGF1RES
RP   GLN-739.
RX   PubMed=15928254; DOI=10.1210/jc.2004-1947;
RA   Kawashima Y., Kanzaki S., Yang F., Kinoshita T., Hanaki K.,
RA   Nagaishi J., Ohtsuka Y., Hisatome I., Ninomoya H., Nanba E.,
RA   Fukushima T., Takahashi S.;
RT   "Mutation at cleavage site of insulin-like growth factor receptor in a
RT   short-stature child born with intrauterine growth retardation.";
RL   J. Clin. Endocrinol. Metab. 90:4679-4687(2005).
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-105; HIS-437; HIS-595; SER-857;
RP   THR-1338 AND VAL-1347.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: This receptor binds insulin-like growth factor 1 (IGF1)
CC       with a high affinity and IGF2 with a lower affinity. It has a
CC       tyrosine-protein kinase activity, which is necessary for the
CC       activation of the IGF1-stimulated downstream signaling cascade.
CC       When present in a hybrid receptor with INSR, binds IGF1.
CC       PubMed:12138094 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long are activated with a high affinity by IGF1, with
CC       low affinity by IGF2 and not significantly activated by insulin,
CC       and that hybrid receptors composed of IGF1R and INSR isoform Short
CC       are activated by IGF1, IGF2 and insulin. In contrast,
CC       PubMed:16831875 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long and hybrid receptors composed of IGF1R and INSR
CC       isoform Short have similar binding characteristics, both bind IGF1
CC       and have a low affinity for insulin.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Manganese.
CC   -!- ENZYME REGULATION: Autophosphorylation activates the kinase
CC       activity.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain.
CC       Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and
CC       SHC1 in vitro when autophosphorylated on tyrosine residues. Forms
CC       a hybrid receptor with INSR, the hybrid is a tetramer consisting
CC       of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1
CC       beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts
CC       with GRB10.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-475981, EBI-475981;
CC       P29353:SHC1; NbExp=1; IntAct=EBI-475981, EBI-78835;
CC       Q6PIS1:SLC23A3; NbExp=1; IntAct=EBI-475981, EBI-2362199;
CC       P61981:YWHAG; NbExp=1; IntAct=EBI-475981, EBI-359832;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Found as a hybrid receptor with INSR in
CC       muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma,
CC       fibroblasts, spleen and placenta (at protein level). Expressed in
CC       a variety of tissues.
CC   -!- PTM: The cytoplasmic domain of the beta subunit is
CC       autophosphorylated on tyrosine residues in response to insulin-
CC       like growth factor I (IGF I).
CC   -!- PTM: Phosphorylation of Tyr-980 is required for IRS1- and SHC1-
CC       binding.
CC   -!- DISEASE: Defects in IGF1R are a cause of insulin-like growth
CC       factor 1 resistance (IGF1RES) [MIM:270450]. It is a disorder
CC       characterized by intrauterine growth retardation and poor
CC       postnatal growth accompanied with increased plasma IGF1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG11657.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org//Genes/IGF1RID40928ch15q26.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/igf1r/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=IGF-1 receptor entry;
CC       URL="http://en.wikipedia.org/wiki/IGF-1_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04434; CAA28030.1; -; mRNA.
DR   EMBL; AB425196; BAG11657.1; ALT_INIT; mRNA.
DR   EMBL; AY332722; AAP81165.1; -; Genomic_DNA.
DR   EMBL; BC113610; AAI13611.1; -; mRNA.
DR   EMBL; BC113612; AAI13613.1; -; mRNA.
DR   EMBL; M69229; AAB59399.1; -; Genomic_DNA.
DR   IPI; IPI00027232; -.
DR   PIR; A25690; IGHUR1.
DR   RefSeq; NP_000866.1; -.
DR   UniGene; Hs.643120; -.
DR   UniGene; Hs.714012; -.
DR   PDB; 1IGR; X-ray; 2.60 A; A=31-492.
DR   PDB; 1JQH; X-ray; 2.10 A; A/B/C=981-1286.
DR   PDB; 1K3A; X-ray; 2.10 A; A=988-1286.
DR   PDB; 1M7N; X-ray; 2.70 A; A/B=974-1294.
DR   PDB; 1P4O; X-ray; 1.50 A; A/B=974-1294.
DR   PDB; 2OJ9; X-ray; 2.00 A; A=982-1286.
DR   PDB; 2ZM3; X-ray; 2.50 A; A/B/C/D=981-1286.
DR   PDB; 3D94; X-ray; 2.30 A; A=986-1286.
DR   PDB; 3F5P; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L/M/R/S/T=981-1286.
DR   PDB; 3I81; X-ray; 2.08 A; A=982-1286.
DR   PDB; 3LVP; X-ray; 3.00 A; A/B/C/D=951-1286.
DR   PDB; 3NW5; X-ray; 2.14 A; A=982-1286.
DR   PDB; 3NW6; X-ray; 2.20 A; A=982-1286.
DR   PDB; 3NW7; X-ray; 2.11 A; A=982-1286.
DR   PDBsum; 1IGR; -.
DR   PDBsum; 1JQH; -.
DR   PDBsum; 1K3A; -.
DR   PDBsum; 1M7N; -.
DR   PDBsum; 1P4O; -.
DR   PDBsum; 2OJ9; -.
DR   PDBsum; 2ZM3; -.
DR   PDBsum; 3D94; -.
DR   PDBsum; 3F5P; -.
DR   PDBsum; 3I81; -.
DR   PDBsum; 3LVP; -.
DR   PDBsum; 3NW5; -.
DR   PDBsum; 3NW6; -.
DR   PDBsum; 3NW7; -.
DR   ProteinModelPortal; P08069; -.
DR   SMR; P08069; 29-926.
DR   DIP; DIP-476N; -.
DR   IntAct; P08069; 23.
DR   MINT; MINT-85902; -.
DR   STRING; P08069; -.
DR   PhosphoSite; P08069; -.
DR   PeptideAtlas; P08069; -.
DR   PRIDE; P08069; -.
DR   Ensembl; ENST00000268035; ENSP00000268035; ENSG00000140443.
DR   GeneID; 3480; -.
DR   KEGG; hsa:3480; -.
DR   UCSC; uc002bul.1; human.
DR   CTD; 3480; -.
DR   GeneCards; GC15P099192; -.
DR   H-InvDB; HIX0038072; -.
DR   HGNC; HGNC:5465; IGF1R.
DR   HPA; CAB010268; -.
DR   MIM; 147370; gene.
DR   MIM; 270450; phenotype.
DR   Orphanet; 73273; Growth delay due to insulin-like growth factor I resistance.
DR   PharmGKB; PA29698; -.
DR   eggNOG; prNOG04495; -.
DR   HOGENOM; HBG316019; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P08069; -.
DR   OMA; TTINNEY; -.
DR   OrthoDB; EOG986BZ0; -.
DR   PhylomeDB; P08069; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; igf1_pathway; IGF1 pathway.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; er_nongenomic_pathway; Plasma membrane estrogen receptor signaling.
DR   DrugBank; DB00047; Insulin Glargine recombinant.
DR   DrugBank; DB00046; Insulin Lyspro recombinant.
DR   DrugBank; DB00030; Insulin recombinant.
DR   DrugBank; DB00071; Insulin, porcine.
DR   DrugBank; DB01277; Mecasermin.
DR   NextBio; 13682; -.
DR   ArrayExpress; P08069; -.
DR   Bgee; P08069; -.
DR   CleanEx; HS_IGF1R; -.
DR   Genevestigator; P08069; -.
DR   GermOnline; ENSG00000140443; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; IC:UniProtKB.
DR   GO; GO:0005792; C:microsome; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043559; F:insulin binding; IPI:BHF-UCL.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL.
DR   GO; GO:0005010; F:insulin-like growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043548; F:phosphoinositide 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0006916; P:anti-apoptosis; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0014065; P:phosphoinositide 3-kinase cascade; IC:BHF-UCL.
DR   GO; GO:0048015; P:phosphoinositide-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IDA:UniProtKB.
DR   InterPro; IPR000494; EGF_rcpt_L.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR020714; Tyr_kinase_insulin_GF_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR002011; Tyr_prot_kinase_rcpt_2_CS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 4.
DR   PANTHER; PTHR23256:SF178; Tyr_kinase_insulin_GF_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; FN_III-like; 3.
DR   SUPFAM; SSF57184; Grow_fac_recept; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cleavage on pair of basic residues;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     30
FT   CHAIN        31    736       Insulin-like growth factor 1 receptor
FT                                alpha chain.
FT                                /FTId=PRO_0000016681.
FT   CHAIN       741   1367       Insulin-like growth factor 1 receptor
FT                                beta chain.
FT                                /FTId=PRO_0000016682.
FT   TOPO_DOM    741    935       Extracellular (Potential).
FT   TRANSMEM    936    959       Helical; (Potential).
FT   TOPO_DOM    960   1367       Cytoplasmic (Potential).
FT   DOMAIN      488    606       Fibronectin type-III 1.
FT   DOMAIN      611    689       Fibronectin type-III 2.
FT   DOMAIN      831    926       Fibronectin type-III 3.
FT   DOMAIN      999   1274       Protein kinase.
FT   NP_BIND    1005   1013       ATP (By similarity).
FT   MOTIF       977    980       IRS1- and SHC1-binding.
FT   ACT_SITE   1135   1135       Proton acceptor (By similarity).
FT   BINDING    1033   1033       ATP.
FT   MOD_RES     980    980       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1161   1161       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1165   1165       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1166   1166       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1339   1339       Phosphoserine.
FT   MOD_RES    1365   1365       Phosphoserine.
FT   MOD_RES    1366   1366       Phosphothreonine.
FT   CARBOHYD     51     51       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    102    102       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    135    135       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    244    244       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    314    314       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    438    438       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    607    607       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    622    622       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    640    640       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    747    747       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    756    756       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    764    764       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    900    900       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    913    913       N-linked (GlcNAc...) (Potential).
FT   DISULFID    215    224       By similarity.
FT   DISULFID    219    230       By similarity.
FT   DISULFID    231    239       By similarity.
FT   DISULFID    235    248       By similarity.
FT   DISULFID    251    260       By similarity.
FT   DISULFID    264    276       By similarity.
FT   DISULFID    282    303       By similarity.
FT   DISULFID    307    321       By similarity.
FT   DISULFID    324    328       By similarity.
FT   VARIANT     105    105       V -> L (in a renal chromophobe sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041424.
FT   VARIANT     138    138       R -> Q (in IGF1RES; has decreased IGF1R
FT                                function).
FT                                /FTId=VAR_034891.
FT   VARIANT     145    145       K -> N (in IGF1RES; has decreased IGF1R
FT                                function).
FT                                /FTId=VAR_034892.
FT   VARIANT     388    388       V -> M (in dbSNP:rs45445894).
FT                                /FTId=VAR_018855.
FT   VARIANT     437    437       R -> H (in dbSNP:rs34516635).
FT                                /FTId=VAR_034893.
FT   VARIANT     511    511       R -> Q (in dbSNP:rs33958176).
FT                                /FTId=VAR_034894.
FT   VARIANT     595    595       R -> H (in dbSNP:rs56248469).
FT                                /FTId=VAR_041425.
FT   VARIANT     605    605       R -> H (in dbSNP:rs45553041).
FT                                /FTId=VAR_018856.
FT   VARIANT     739    739       R -> Q (in IGF1RES; leads to failure of
FT                                processing of the IGF1R proreceptor to
FT                                mature IGF1R).
FT                                /FTId=VAR_034895.
FT   VARIANT     808    808       H -> R (in dbSNP:rs34061581).
FT                                /FTId=VAR_034896.
FT   VARIANT     828    828       A -> T (in dbSNP:rs35224135).
FT                                /FTId=VAR_034897.
FT   VARIANT     857    857       N -> S (in dbSNP:rs45611935).
FT                                /FTId=VAR_041426.
FT   VARIANT    1338   1338       A -> T (in dbSNP:rs34102392).
FT                                /FTId=VAR_041427.
FT   VARIANT    1347   1347       A -> V (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041428.
FT   MUTAGEN     980    980       Y->F: Reduces tyrosine phosphorylation.
FT                                Abolishes interaction with IRS1 and SHC1.
FT                                Does not abolish interaction with PIK3R1,
FT                                nor with GRB10.
FT   MUTAGEN    1033   1033       K->A: Kinase inactive. Abolishes tyrosine
FT                                phosphorylation and abolishes interaction
FT                                with IRS1, SHC1 and PIK3R1.
FT   MUTAGEN    1280   1280       Y->F: No effect on GRB10-binding.
FT   MUTAGEN    1281   1281       Y->F: No effect on GRB10-binding.
FT   MUTAGEN    1346   1346       Y->F: Loss of GRB10-binding.
FT   CONFLICT    928    929       TG -> R (in Ref. 3; BAG11657).
FT   STRAND       37     41
FT   HELIX        43     49
FT   STRAND       53     57
FT   STRAND       59     65
FT   STRAND       68     70
FT   STRAND       80     83
FT   STRAND       85     92
FT   HELIX        96     98
FT   STRAND      115    121
FT   STRAND      138    144
FT   HELIX       157    160
FT   HELIX       164    166
FT   STRAND      168    171
FT   HELIX       175    178
FT   TURN        183    188
FT   STRAND      194    199
FT   STRAND      201    203
FT   STRAND      205    209
FT   HELIX       217    219
FT   STRAND      235    241
FT   STRAND      247    255
FT   STRAND      257    263
FT   STRAND      269    271
FT   TURN        272    274
FT   STRAND      275    277
FT   HELIX       279    283
FT   STRAND      297    299
FT   STRAND      302    306
FT   STRAND      311    315
FT   STRAND      321    323
FT   STRAND      325    327
FT   STRAND      331    341
FT   HELIX       345    347
FT   TURN        349    352
FT   STRAND      354    362
FT   HELIX       375    378
FT   STRAND      383    386
FT   STRAND      388    392
FT   TURN        415    417
FT   STRAND      418    423
FT   TURN        434    436
FT   STRAND      440    443
FT   STRAND      445    451
FT   HELIX       456    466
FT   STRAND      474    477
FT   TURN        479    481
FT   STRAND      980    982
FT   STRAND      998   1007
FT   STRAND     1009   1022
FT   STRAND     1025   1034
FT   HELIX      1041   1051
FT   HELIX      1052   1056
FT   STRAND     1065   1069
FT   STRAND     1071   1074
FT   STRAND     1076   1080
FT   HELIX      1087   1094
FT   HELIX      1109   1128
FT   HELIX      1138   1140
FT   STRAND     1141   1143
FT   STRAND     1149   1151
FT   HELIX      1176   1178
FT   HELIX      1181   1186
FT   HELIX      1191   1206
FT   TURN       1212   1215
FT   HELIX      1218   1226
FT   HELIX      1239   1248
FT   HELIX      1253   1255
FT   HELIX      1259   1264
FT   HELIX      1267   1269
FT   HELIX      1274   1277
SQ   SEQUENCE   1367 AA;  154793 MW;  AE8A735F87F745C8 CRC64;
     MKSGSGGGSP TSLWGLLFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGYLH
     ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
     EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTVDWSLI LDAVSNNYIV GNKPPKECGD
     LCPGTMEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSTCG KRACTENNEC CHPECLGSCS
     APDNDTACVA CRHYYYAGVC VPACPPNTYR FEGWRCVDRD FCANILSAES SDSEGFVIHD
     GECMQECPSG FIRNGSQSMY CIPCEGPCPK VCEEEKKTKT IDSVTSAQML QGCTIFKGNL
     LINIRRGNNI ASELENFMGL IEVVTGYVKI RHSHALVSLS FLKNLRLILG EEQLEGNYSF
     YVLDNQNLQQ LWDWDHRNLT IKAGKMYFAF NPKLCVSEIY RMEEVTGTKG RQSKGDINTR
     NNGERASCES DVLHFTSTTT SKNRIIITWH RYRPPDYRDL ISFTVYYKEA PFKNVTEYDG
     QDACGSNSWN MVDVDLPPNK DVEPGILLHG LKPWTQYAVY VKAVTLTMVE NDHIRGAKSE
     ILYIRTNASV PSIPLDVLSA SNSSSQLIVK WNPPSLPNGN LSYYIVRWQR QPQDGYLYRH
     NYCSKDKIPI RKYADGTIDI EEVTENPKTE VCGGEKGPCC ACPKTEAEKQ AEKEEAEYRK
     VFENFLHNSI FVPRPERKRR DVMQVANTTM SSRSRNTTAA DTYNITDPEE LETEYPFFES
     RVDNKERTVI SNLRPFTLYR IDIHSCNHEA EKLGCSASNF VFARTMPAEG ADDIPGPVTW
     EPRPENSIFL KWPEPENPNG LILMYEIKYG SQVEDQRECV SRQEYRKYGG AKLNRLNPGN
     YTARIQATSL SGNGSWTDPV FFYVQAKTGY ENFIHLIIAL PVAVLLIVGG LVIMLYVFHR
     KRNNSRLGNG VLYASVNPEY FSAADVYVPD EWEVAREKIT MSRELGQGSF GMVYEGVAKG
     VVKDEPETRV AIKTVNEAAS MRERIEFLNE ASVMKEFNCH HVVRLLGVVS QGQPTLVIME
     LMTRGDLKSY LRSLRPEMEN NPVLAPPSLS KMIQMAGEIA DGMAYLNANK FVHRDLAARN
     CMVAEDFTVK IGDFGMTRDI YETDYYRKGG KGLLPVRWMS PESLKDGVFT TYSDVWSFGV
     VLWEIATLAE QPYQGLSNEQ VLRFVMEGGL LDKPDNCPDM LFELMRMCWQ YNPKMRPSFL
     EIISSIKEEM EPGFREVSFY YSEENKLPEP EELDLEPENM ESVPLDPSAS SSSLPLPDRH
     SGHKAENGPG PGVLVLRASF DERQPYAHMN GGRKNERALP LPQSSTC
//
